top of page
Immunotherapy includes strategies to enhance immune cell activation in patients to better target cancer.
​Cellmover has developed a library of peptides and nanobodies directed at specific proteins in T cells and NK cells. By targeting these proteins, the peptides and nanobodies mediate increased survival and persistence of immune cells within the tumor microenvironment.
Pipeline
Cellmover currently has three lead projects, focusing on specific targets in immune cells.
Project
Target
Discovery
Pre-clinical
Phase I
CM101
CM102
CM103
intracellular
extracellular
intracellular
bottom of page